Minneapolis Clinical Trials
2031 Study (Renal)
To evaluate the safety and tolerability of SEP-363856 in males and females with severe renal impairment and those on hemodialysis
6 nights
1 visits
The purpose of Study 2031 is to evaluate the safety and tolerability of SEP-363856 in males and females with severe renal impairment and those on hemodialysis.
Participation in the study requires an overnight stay in the Nucleus Network Clinic.
This study has been approved by an independent ethics committee.
Reimbursement for study participation will be provided for time and travel from $2,150 to $4,100.
Call Jenna at 651-724-0500 or register your interest to discuss your eligibility today!
Eligibility
Biological Sex Male or Female
Age 18 to 70 years old
BMI 18 to 40.0
Medications Medications and conditions must be stable in the opinion of the study doctor